Drug Profile
Research programme: cancer vaccines - EpiThany
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator EpiThany
- Class Antigens; Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bladder cancer; Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Bladder-cancer in USA (Parenteral)
- 28 Mar 2024 No recent reports of development identified for research development in Colorectal-cancer in USA (Parenteral)
- 28 Mar 2024 No recent reports of development identified for research development in Non-small-cell-lung-cancer in USA (Parenteral)